The Medicare GLP-1 Bridge opens July 1, 2026 entirely outside Part D, at a $245 negotiated monthly net price with a $50 beneficiary copay and a Humana-operated central processor no plan touches. Part D sponsors carry zero GLP-1 obesity drug cost risk through December 2027.
That makes the 2027 bid simpler. It makes the 2028 bid harder, because the BALANCE model that would pull sponsors back into the chain is paused with its pricing, utilization, and eligibility parameters unpublished.
Key Takeaways
- The Bridge runs on Section 402 demonstration authority for 18 months, July 1, 2026 through December 31, 2027, with no announced extension mechanism.
- Bridge claims do not count toward Part D financial reporting, gross covered prescription drug costs, direct subsidy, or risk corridors. Within Part D they do not exist.
- Eligibility gates on comorbidity, not BMI alone, which selects members whose risk scores run above 1.8 and whose annual total cost of care exceeds $20,000.
- The $50 copay is excluded from TrOOP and from LIS cost-sharing reductions, so for dual-eligible members it is a net new expense the subsidy does not cover.
- BALANCE paused on April 21, 2026 after missing the 80% NAMBA-weighted enrollment threshold, leaving 2028 bids to be filed against unpublished parameters.
A Payment Channel Built Beside Part D, Not Inside It
Section 402 demonstration authority is what lets CMS route this outside the benefit entirely, and the routing is the whole design.
Humana processes claims on an enhanced version of the LI NET infrastructure that already handles Part D gap coverage for low-income beneficiaries awaiting enrollment, chosen because it reaches essentially every Medicare network pharmacy without plan-level integration. The chain runs four steps: the beneficiary presents at any network pharmacy and pays $50; the claim routes to the Humana processor, which reimburses the pharmacy at no less than wholesale acquisition cost minus the copay plus a dispensing fee; the manufacturer remits to CMS the difference between WAC and the $245 negotiated price; the federal government absorbs the net cost.
No plan appears anywhere in it. Sponsors do not opt in, and Bridge drugs do not touch Part D financial reporting, gross covered prescription drug costs, direct subsidy calculations, or risk corridor exposure.
Three drug families qualify. Wegovy, at a pre-deal list price around $1,350 per month, prices at $245. Zepbound, restricted to the KwikPen formulation and previously above $1,080, also prices at $245. Foundayo, Eli Lilly's oral agent approved April 1, 2026, enters with self-pay pricing from $149 for the lowest dose, and its Bridge treatment has not been specified under the same framework, which matters because oral formulations have shown higher adherence.
What survives the carve-out is the existing formulary duty. Plans may not cut access to GLP-1 receptor agonists approved for diabetes or cardiovascular indications because the obesity indication now runs through the Bridge, and appeals on those prescriptions still run the standard Part D process.
The Gate Keeps the Cost and Removes the Drug
Eligibility is narrower than the headline BMI figure, and the way it is narrowed is what makes it actuarially interesting.
Tier one requires a BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or above. Tier two requires a BMI of 27 or higher plus pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. Roughly 14 million Medicare beneficiaries carried overweight or obesity diagnoses in 2020 claims data, but that is the wrong denominator: both a BMI threshold and a qualifying diagnosis are required, which puts the clinically eligible pool nearer 6 to 9 million.
Those qualifying conditions are the same ones that place beneficiaries in the highest HCC tiers. A tier-one heart failure or CKD member typically carries a risk score above 1.8 and annual total cost of care well above $20,000. The Bridge lifts the GLP-1 drug cost off the plan and leaves every hospitalization and Part A utilization dollar exactly where it was.
So the plan holds the medical risk of its sickest members while a federal processor pays for the therapy that might reduce it. If the SELECT trial's 20% relative reduction in major adverse cardiovascular events holds in this population, the offsets arrive after the 18-month window closes, and only for members who stay in the same plan and maintain adherence. Standard bid frameworks model that badly, because they do not carry cross-bucket interactions between pharmacy and Part A and B medical cost inside one planning cycle.
The copay accounting cuts both ways. Excluding it from TrOOP means a bridged member accrues only on formulary drugs, which keeps some members short of the $2,100 cap and out of the catastrophic phase, where liability sits heavily on sponsors since the redesign cut federal reinsurance. That trims exposure at a phase running roughly 22% above actuarial base cases in year one. But LIS beneficiaries cannot apply cost-sharing reductions to the $50, so for duals whose cost sharing is otherwise eliminated it is a new expense, and an access barrier in exactly the segment with the most to gain clinically.
The 2028 Bid Files Before the Parameters Exist
BALANCE is paused rather than cancelled, which is why its March 2026 request for applications still governs planning it cannot actually support.
CMS introduced the model in December 2025, issued the RFA in March 2026, set an April 20 application deadline, and paused on April 21 after enrollment fell short of the 80% NAMBA-weighted threshold in Section 2.3.1. The Bridge extension through December 2027 followed as the substitute.
The RFA settles some terms. Enhanced Alternative plans and employer group waiver plans would carry a $50 copay per fill and standard plans $125; catastrophic cost sharing would be eliminated for covered drugs; all qualifying drugs would sit on formulary without tier discrimination; risk corridors would apply at 2.5% thresholds rather than 5%, and only above one standard deviation of mean national utilization.
It settles none of the assumptions a bid needs. Whether the $245 price carries over, what utilization CMS would use to set the benchmark, whether eligibility keeps the comorbidity gate or widens to BMI 27 without it, whether oral agents are covered separately, and whether LIS members keep cost sharing are all open. Plans file 2028 bids in mid-2027, roughly six months before CMS is likely to answer any of it.
The published projections do not narrow the range either, because they bracket uptake rather than price.
| Source | Eligible Population | Projected Year-1 Users | 10-Year Net Federal Cost | Drug Cost Assumption |
|---|---|---|---|---|
| CBO (October 2024) | 12.5 million | 0.3 million (2%) | ~$35 billion | Standard Part D cost sharing |
| JAMA/Hwang et al. (April 2025) | 30 million cumulative | 3 million (base case) | $47.7 billion net | ~$8,412/year semaglutide |
| American Action Forum (November 2025) | ~54.8 million Part D enrollees | 2.2 million (mid-range) | ~$3.8 billion/year at steady state | $245/month manufacturer net price |
CBO's estimate predates the Bridge and assumed standard Part D cost sharing, modeling only 0.3 million users in year one against 12.5 million newly eligible, with per-user cost near $5,600 in 2026 falling to $4,300 by 2034. The JAMA microsimulation assumed 10% uptake with 40% long-term adherence at roughly $8,412 per year for semaglutide, producing $47.7 billion net against $65.9 billion gross and $18.2 billion of medical offsets, a 27.6% offset ratio. The $245 monthly price annualizes to $2,940 before the $600 of copays, roughly 65% under that drug cost assumption.
Both point the same direction: real uptake should exceed the base cases, because the affordability barrier both models priced in has been removed. The $50 copay is a 96% cut from Wegovy's pre-Bridge list price, in a population with higher obesity prevalence and lower average income than the commercially insured. What the 18 months will not produce is adherence, offset, and uptake experience credible enough to bid 2028 on, which is the same gap the BALANCE enrollment threshold failed to clear.
Further Reading
- The four simultaneous semaglutide prices behind the GLP-1 projection problem - Milliman’s August 2026 collection of the $274 maximum fair price, the $245 Bridge price, cash-pay and list, and what persistency does to cost per starter.
- CMS GLP-1 Bridge Sets $50 Copay, Rewriting Part D Actuarial Math - The May 2026 actuarial analysis of the Bridge announcement covering BALANCE model failure, federal cost projections, and 2027 bid construction implications before full operational guidance was published.
- Medicare Part D 2026: Year-One Redesign Data Flips Key Actuarial Assumptions - First full year of CMS Part D financial data under the IRA redesign, showing 14% unfavorable bid variance and 22% catastrophic phase utilization overshoot that provides the baseline against which Bridge utilization will be measured.
- CMS 2027 MA Rate Reversal: What 2.48% Means for Plan Actuaries - The rate environment and revenue compression that Part D and MA-PD plans are navigating alongside the GLP-1 Bridge launch and BALANCE uncertainty.
- CY2027 MA Bids: Actuaries Navigate Tighter Margins - The 2027 MA bid environment and margin compression that constrains how aggressively plans can price GLP-1 BALANCE scenarios into 2028 bids.
- Stop-Loss Carriers Rewrite GLP-1 Rules at 2026 Renewals - The commercial-market parallel to the Bridge: how stop-loss carriers are managing GLP-1 cost exposure through lasers, carve-outs, and raised attachment points.
- Medicare Advantage Actuarial Guide - Star ratings, bid strategy, and MA plan financial dynamics as context for Bridge-period planning.
- CMS-4215-P Locks Mandatory MFP Formulary Inclusion Into Part D Bid Math - The proposed permanent negotiation framework that would remove formulary-exclusion flexibility for MFP drugs, a separate structural constraint on 2028 bid design from the Bridge's copay mechanics.
Sources
- CMS: Medicare GLP-1 Bridge Program (Official Program Page, June 2026)
- AMCP: Regulatory NewsBREAK: CMS Releases FAQs on the Medicare GLP-1 Bridge (March 2026)
- KFF: What to Know About the BALANCE Model and Medicare GLP-1 Bridge (Updated April 2026)
- Medicare Rights Center: GLP-1 Weight-Loss Drug Demonstration Begins July 2026
- STAT News: Medicare $50 Weight Loss Drugs Could Cost Taxpayers Billions (April 2026)
- Reed Smith: CMS Provides Details for Medicare GLP-1 Bridge Coverage (May 2026)
- KFF: What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries (May 2026)
- JAMA Health Forum: Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists (Hwang et al., April 2025)
- CBO: How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget? (October 2024)
- American Action Forum: GLP-1 Coverage Determination Cost Analysis (November 2025)
- On Healthcare Tech: The BALANCE Model Pause (April 23, 2026)